Clinical Trial Update: Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating oral pazopanib plus oral topotecan given in a metronomic antiangiogenic regimen for recurrent glioblastoma multiforme, includi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Neoplasms
• Central Nervous System Neoplasms
• Glioblastoma
• Glioblastoma Multiforme
• Gliosarcoma

Drugs mentioned

• Hycamtin (Topotecan)
• Votrient (Pazopanib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Glioblastoma, Glioblastoma Multiforme | Phase 2 | Status: COMPLETED | Results posted: 2020-09-18